January 23, 2023 07:18 AM ESTUpdated 11:33 AM
Deals

Up­dat­ed: J&J ax­es four-year dis­cov­ery al­liance with Mor­phic

Amber Tong

J&J and Har­vard spin­out Mor­phic Ther­a­peu­tic are part­ing ways af­ter four years of work­ing to­geth­er on find­ing small mol­e­cule drugs that can act on new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times